Clonal Hematopoiesis of indeterminate potential (CHIP) has been increasingly recognised as a risk factor for cardiovascular disease (CVD). Recent epidemiological and experimental studies have linked CHIP as an independent risk factor for myocardial infarction, stroke, and coronary artery disease, with specific mutations carrying a higher CVD risk. During the aging process, somatic mutations in genes, including DNMT3A and TET2, accumulate in the hematopoietic stem cells (HSCs), conferring both epigenetic and metabolic advantages that not only drive hematopoiesis towards a pro-inflammatory myeloid lineage but also reprogram innate immune cells, promoting a persistent inflammatory state. These myeloid derivatives, via increased IL-1β and IL-6 production, establish a pro-atherogenic environment and contribute to plaque instability, leading to an increased thrombotic risk and accelerated vascular aging. Although routine screening is not recommended for asymptomatic adults, targeted detection in high-risk individuals could benefit from preventive strategies. Incorporating CHIP into risk models may enable precision prevention, but prospective trials are needed to determine whether CHIP-guided interventions improve cardiovascular outcomes.

Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic diseases sharing ineffective hematopoiesis, cytopenias, and a high risk of evolution to acute myeloid leukemia (AML). The current MDS classification systems, such as the International Consensus Classification (ICC) and the WHO 2022 classification, have incorporated molecular and cytogenetic markers to improve the stratification of risk and guide therapy. However, treatment options for high-risk MDS (HR-MDS) remain limited, with hypomethylating agents (HMAs) providing only modest survival benefits. Emerging treatments such as immune checkpoint blockade and novel targeted therapies could further improve patient outcomes. While early excitement was significant, clinical trials of the immune checkpoint inhibitors (ICIs) ipilimumab and durvalumab have produced no definitive results, highlighting the need for better patient selection and combination regimens. Emerging drugs luspatercept and imetelstat have been suggested for lower-risk MDS (LR-MDS) by promoting transfusion independence and global hematologic response. In contrast, exploratory agents such as pevonedistat, magrolimab, and sabatolimab are under further investigation for HR-MDS. The future of MDS treatment currently addresses precision medicine, in which molecular characterization guides therapeutic options. Identification of predictive biomarkers for response to targeted therapies and immunotherapies is crucial to optimize patient outcomes. An integrated, patient-centered approach combining genomics, novel therapeutics, and immunomodulation is therefore essential to address the current needs in MDS management.

Background: Dilated cardiomyopathy (DCM) is a progressive myocardial disease characterized by ventricular dilation and impaired systolic function, often leading to heart failure and increased mortality. This study aims to analyze DCM-related mortality trends among adults in the United States from 1999 to 2023. Methods: Trends in DCM-related mortality among adults aged ≥ 25 years from 1999 to 2023 were analyzed using the CDC WONDER multiple-cause of death database. Age adjusted mortality rates (AAMRs) per 100,000 persons and annual percent change (APC) were calculated and stratified by year, sex, race, census region and urbanization status. Results: From 1999 to 2023, there were 184,073 deaths in the United States attributed to DCM. Over this period, the AAMR declined from 5.19 in 1999 to 2.34 in 2023. Between 1999 and 2002, the AAMR decreased significantly from 5.19 to 4.38 (APC −6.20* [95% CI, −12.42 to −0.72; P = 0.0208]). The trend remained stable between 2002 and 2005, followed by a significant decline between 2005 and 2014, where the AAMR decreased from 4.96 to 2.66 (APC −6.84* [95% CI, −9.00 to −3.05; P = 0.0300]). The trend then remained relatively unchanged from 2014 to 2023. In 2023, males (3.4) averaged a considerably higher AAMR than females (1.38). Among racial groups, the highest AAMR in 2023 was reported in the Non-Hispanic (NH) Black group (3.77), followed by the NH White group (2.3), the Hispanics and Latinos (1.67) and the NH Others group (NH Asians and NH Native American Indian or Alaskan Native) at 1.23. Overall from 1999 to 2020, rural areas (3.52) averaged a significantly higher AAMR than urban areas (3.50). Regionally, in 2023, the Western region averaged the highest AAMR at 2.69, followed by the South at 2.31, the Midwest at 2.42 and lastly the Northeast at 1.83. Conclusion: Our analysis revealed a significant decline in DCM-related mortality rates in the United States from 1999 to 2023, with the most substantial reductions occurring between 1999 and 2014. However, disparities persist, with higher mortality rates observed in males, NH Black individuals, and rural populations. Regional variations also highlight the need for targeted interventions to further reduce the burden of DCM.

Background: Patient education is essential for management of CVD as it enables in earlier diagnosis, early treatment and prevention of complications. Artificial intelligence is and increasingly popular resource with applications in virtual patient counselling. Thus, the study aimed to compare the AI generated response for patient education guide on common cardiovascular diseases using ChatGPT and Google Gemini. Methods: The study assessed the responses generated by ChatGPT 3.5 and Google Gemini for patient education brochure on angina, hypertension, and cardiac arrest. Number of words, sentences, average word count per sentence, average syllables per word, grade level, and ease level were assessed using Flesch-Kincaid Calculator, and similarity score was checked using Quillbot. Reliability was assessed using modified DISCERN score. The statistical analysis was done using R version 4.3.2. Results: The statistical analysis exhibited that there were no statistically significant differences between the responses generated by the AI tools based on different variables except for the ease score (p=0.2043), which was statistically superior for ChatGPT. The correlation coefficient between both the two tools was negative for the ease score (r=-0.9986, p=0.0332), the reliability score (r=-0.8660, p=0.3333), but was statistically significant for ease score. Conclusions: The study demonstrated no significant differences between the responses generated by the AI tools for patient education brochures. Further research must be done to assess the ability of the AI tools, and ensure accurate and latest information is being generated, to benefit overall public well-being.

Multiple myeloma, the second most common hematologic malignancy, accounts for approximately 10% of all blood cancers. Therapeutic advances have transformed multiple myeloma from a uniformly fatal disease into a chronic, manageable condition. Autologous stem cell transplantation (ASCT) remains a cornerstone of frontline treatment, demonstrating superiority in progression-free survival (PFS) and minimal residual disease (MRD) negativity compared with chemotherapy alone or modern induction regimens without transplant. International guidelines continue to recommend ASCT as the standard of care for eligible patients. Maintenance therapy post ASCT further improves PFS and overall survival, although it carries a modestly increased risk of secondary malignancies. Meanwhile, novel immunotherapies, including chimeric antigen receptor T cells and bispecific antibodies, are reshaping treatment strategies, showing strong efficacy in relapsed/refractory multiple myeloma. Ongoing trials are evaluating their role in frontline settings, with the potential to complement or replace ASCT. The future of multiple myeloma management hinges on precision medicine, using MRD assessment, genomic profiling, and patient-specific risk stratification to guide therapy. As these personalized approaches are integrated alongside established therapies, the goal of achieving long-term remission and potentially a cure becomes increasingly attainable.

Background Dilated cardiomyopathy (DCM) is a progressive myocardial disease characterized by ventricular dilation and impaired systolic function, often leading to heart failure and increased mortality. This study aims to analyze DCM-related mortality trends among adults in the United States from 1999 to 2023. Methods Trends in DCM-related mortality among adults aged ≥ 25 years from 1999 to 2023 were analyzed using the CDC WONDER multiple-cause of death database. Age adjusted mortality rates (AAMRs) per 100,000 persons and annual percent change (APC) were calculated and stratified by year, sex, race, census region and urbanization status. Results From 1999 to 2023, there were 184,073 deaths in the United States attributed to DCM. Over this period, the AAMR declined from 5.19 in 1999 to 2.34 in 2023. Between 1999 and 2002, the AAMR decreased significantly from 5.19 to 4.38 (APC -6.20* [95% CI, -12.42 to -0.72; P = 0.0208]). The trend remained stable between 2002 and 2005, followed by a significant decline between 2005 and 2014, where the AAMR decreased from 4.96 to 2.66 (APC -6.84* [95% CI, -9.00 to -3.05; P = 0.0300]). The trend then remained relatively unchanged from 2014 to 2023 (figure 1). In 2023, males (3.4) averaged a considerably higher AAMR than females (1.38) (figure 1). Among racial groups, the highest AAMR in 2023 was reported in the Non-Hispanic (NH) Black group (3.77), followed by the NH White group (2.3), the Hispanics and Latinos (1.67) and the NH Others group (NH Asians and NH Native American Indian or Alaskan Native) at 1.23 (figure 2). Overall from 1999 to 2020, rural areas (3.52) averaged a significantly higher AAMR than urban areas (3.50). Regionally, in 2023, the Western region averaged the highest AAMR at 2.69, followed by the South at 2.31, the Midwest at 2.42 and lastly the Northeast at 1.83. Trends in dilated cardiomyopathy-related mortality in the United States (1999–2023), stratified by overall population and sex Trends in dilated cardiomyopathy-related mortality in the United States (1999–2023), stratified by race Conclusion Our analysis revealed a significant decline in DCM-related mortality rates in the United States from 1999 to 2023, with the most substantial reductions occurring between 1999 and 2014. However, disparities persist, with higher mortality rates observed in males, NH Black individuals, and rural populations. Regional variations also highlight the need for targeted interventions to further reduce the burden of DCM.